180 related articles for article (PubMed ID: 147811)
21. Primary structure of human fibrinogen and fibrin. Isolation and partial characterization of chains of fragment D.
Collen D; Kudryk B; Hessel B; Blombäck B
J Biol Chem; 1975 Aug; 250(15):5808-17. PubMed ID: 125279
[TBL] [Abstract][Full Text] [Related]
22. Calcium modulates plasmin cleavage of the fibrinogen D fragment gamma chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the gamma chain.
Odrljin TM; Rybarczyk BJ; Francis CW; Lawrence SO; Hamaguchi M; Simpson-Haidaris PJ
Biochim Biophys Acta; 1996 Nov; 1298(1):69-77. PubMed ID: 8948490
[TBL] [Abstract][Full Text] [Related]
23. Preparation and characterization of NH2-terminal fibrinogen B beta fragments from N-DSK of human fibrinogen.
Birken S; Agosto G; Lahiri B; Canfield R
Thromb Haemost; 1984 Feb; 51(1):16-21. PubMed ID: 6232727
[TBL] [Abstract][Full Text] [Related]
24. Terminal plasmin degradation products D and E of duck fibrinogen and their effect on polymerization of fibrin.
Krajewski T; Nowak P; Cierniewski C
Acta Biochim Pol; 1985; 32(2):144-54. PubMed ID: 4036448
[TBL] [Abstract][Full Text] [Related]
25. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.
Francis CW; Marder VJ; Barlow GH
J Clin Invest; 1980 Nov; 66(5):1033-43. PubMed ID: 6448866
[TBL] [Abstract][Full Text] [Related]
26. [Interaction of heavy and light chains of plasmin with fibrinogen E and D fragments].
Kudinov SA; Lezhen TI
Biokhimiia; 1984 Dec; 49(12):2003-7. PubMed ID: 6240993
[TBL] [Abstract][Full Text] [Related]
27. Purification and partial characterization of a D-like fragment from human fibrinogen, produced by human leukocyte elastase.
Sterrenberg L; Nieuwenhuizen W; Hermans J
Biochim Biophys Acta; 1983 Jan; 755(2):300-6. PubMed ID: 6550499
[TBL] [Abstract][Full Text] [Related]
28. The alpha(E)C domain of human fibrinogen-420 is a stable and early plasmin cleavage product.
Applegate D; Steben LS; Hertzberg KM; Grieninger G
Blood; 2000 Apr; 95(7):2297-303. PubMed ID: 10733499
[TBL] [Abstract][Full Text] [Related]
29. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Carroll RC; Lockhart MS; Taylor FB
J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
[TBL] [Abstract][Full Text] [Related]
30. Plasmic degradation of human fibrinogen. IV. Identification of subunit chain remnants in fragment Y.
Furlan M; Seelich T; Beck EA
Biochim Biophys Acta; 1975 Jul; 400(1):112-20. PubMed ID: 125108
[TBL] [Abstract][Full Text] [Related]
31. Characterization of fragment E from fibrinogen and cross-linked fibrin.
Slade CL; Pizzo SV; Taylor LM; Steinman HM; McKee PA
J Biol Chem; 1976 Mar; 251(6):1591-6. PubMed ID: 815259
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the terminal degradation products of canine fibrinogen by plasmin.
Chen JP; Hutchison HT; Nanninga LB; Guest MM
Biochim Biophys Acta; 1975 Mar; 386(1):69-79. PubMed ID: 123781
[TBL] [Abstract][Full Text] [Related]
33. Isolation of fibrin(ogen) degradation products from normal plasma by affinity chromatographic study.
Vila V; Regañon E; Aznar J
Clin Chim Acta; 1978 Jul; 87(2):245-52. PubMed ID: 95911
[TBL] [Abstract][Full Text] [Related]
34. Distinction between fibrinogen and fibrin degradation products in plasma.
Gaffney PJ
Clin Chim Acta; 1975 Nov; 65(1):109-15. PubMed ID: 1192601
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunoassay of an early plasmin degradation product of human fibrinogen, "fragment A", and its clinical application.
Takagi K; Kawai T
Thromb Haemost; 1978 Feb; 39(1):1-11. PubMed ID: 148116
[TBL] [Abstract][Full Text] [Related]
36. Physicochemical and biological properties of human and canine plasmins.
Takeda Y; Nakabayashi M
J Clin Invest; 1974 Jan; 53(1):154-62. PubMed ID: 4128408
[TBL] [Abstract][Full Text] [Related]
37. Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: amino-terminal sequences of intermediate and terminal fragments.
Takagi T; Doolittle RF
Biochemistry; 1975 Mar; 14(5):940-6. PubMed ID: 123758
[TBL] [Abstract][Full Text] [Related]
38. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
vanDeWater L; Carr JM; Aronson D; McDonagh J
Blood; 1986 May; 67(5):1468-73. PubMed ID: 2938648
[TBL] [Abstract][Full Text] [Related]
39. Plasmic degradation of bovine fibrinogen and non-crosslinked fibrins in solution and in gel form.
Inoue N; Moroi M; Yamasaki M
Biochim Biophys Acta; 1975 Aug; 400(2):322-33. PubMed ID: 240417
[TBL] [Abstract][Full Text] [Related]
40. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property.
Jandu N; Richardson M; Singh G; Hirte H; Hatton MW
Int J Gynecol Cancer; 2006; 16(4):1536-44. PubMed ID: 16884362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
